|
**Overview**: **tTG DGP Combined Screen Panel****Introduction**: The Tissue Transglutaminase DGP Combined Screen Panel is a diagnostic tool designed for celiac disease screening using serum samples. In India, celiac disease prevalence is ~0.8-1.5 percent (higher in North India, wheat-consuming regions), often underdiagnosed in rural/low-SES children/adults with chronic diarrhea, failure to thrive, anemia, or short stature due to gluten sensitivity. High morbidity from under-testing leading to delayed gluten-free diet, causing malnutrition, osteoporosis, or lymphoma risk. Per gastroenterology practices aligned with ICMR, Indian Society of Gastroenterology, and Pediatric Gastroenterology guidelines, the test employs immunoassay for tTG IgA, tTG IgG, DGP IgA, and DGP IgG over 1â€"2 days with high accuracy, valuable for sensitive/specific celiac detection (tTG IgA + DGP IgA >95 percent sensitivity in symptomatic). This diagnostic falls under autoimmune screening and targets patients with GI symptoms, anemia, or family history, addressing accurate detection to guide gluten-free diet and biopsy confirmation. With elevated morbidity due to underdiagnosis, the test supports public health efforts by enabling early celiac profiling and reducing nutritional complications. Its serum-based approach ensures reliable autoantibody assessment.**Other Names**: tTG DGP Pnl.**FDA Status**: FDA approved, CLIA certified for biochemistry/immunology, compliant with 2025 standards.**Historical Milestone**: tTG + DGP combined standard in celiac diagnosis; in India, expanding in pediatric/GI clinics.**Purpose**: The test assesses 4 parameters including tTG IgA to guide celiac disease screening, detect autoantibodies, inform gluten-free diet.**Test Parameters**: 1. tTG IgA, 2. tTG IgG, 3. DGP IgA, 4. DGP IgG.**Pretest Condition**: No fasting required; patients should have GI symptoms.**Specimen**: 3 mL serum in 1 SST, transported within specified times to maintain sample viability.**Sample Stability at Room Temperature**: 8 hours with proper handling to preserve antibody integrity, ensuring reliable test performance.**Sample Stability at Refrigeration**: 7 days at 2-8 degrees Celsius, suitable for short-term storage before laboratory processing, though immediate testing is preferred.**Sample Stability at Frozen**: 6 months at -20 degrees Celsius, allowing long-term storage for retesting, though freezing may affect some analytes.**Medical History**: Patients should provide details on diarrhea, weight loss, anemia.**Consent**: Written informed consent is required, detailing the test's purpose, potential risks of undetected celiac including malnutrition, benefits of screening, and minimal discomfort from venipuncture.**Procedural Considerations**: The test involves sample processing using immunoassay by trained personnel to ensure sterile technique, avoid hemolysis, and interpret results within 1â€"2 days using provided controls. Laboratories must maintain a controlled environment, adhere to quality assurance protocols.**Factors Affecting Result Accuracy**: Delays beyond stability periods, improper storage conditions, hemolysis can affect results. Correlation with clinical evaluation or additional testing is recommended to confirm findings.**Clinical Significance**: Positive tTG IgA/DGP IgA strongly supports celiac diagnosis, necessitating specialist input.**Specialist Consultation**: Gastroenterologists should be consulted for management.**Additional Supporting Tests**: Duodenal biopsy, HLA-DQ2/DQ8 for confirmation.**Test Limitations**: IgA deficiency false negatives; comprehensive approach required.**References**: Indian Journal of Gastroenterology 2024, Celiac Studies India 2023. |
